rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Scott Juda

Director

Company insider

Files Form 4 as: Director, INmune Bio.

Every Form 4 they filed

In numbers

Trades disclosed
38
Buys
7
Sells
0
Bought
$455K
Sold
$0
Companies
1
Companies where not an officer
1
First trade
3 Jun 2019
Last trade
2 Jul 2026
Last filed
7 Jul 2026

Companies traded

Everywhere else they filed: board seats, 10% stakes, other companies
INMB INmune BioDirector · Biotechnology · last 2 Jul 20267 buys · 0 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
101Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
2 Jul 2026filed 7 Jul 2026INMB INmune BioBiotechnologySEC FORM 4 Code M$21K14,801 at $1.40filing
2 Jul 2026filed 7 Jul 2026INMB INmune Biooption or derivative · BiotechnologySEC FORM 4 Code X$1,85014,801 at $0.125filing
2 Jul 2026filed 7 Jul 2026INMB INmune Biooption or derivative · BiotechnologySEC FORM 4 Code X$1,92414,801 at $0.13filing
2 Jul 2026filed 7 Jul 2026INMB INmune BioBiotechnologySEC FORM 4 Code M$21K14,801 at $1.40filing
1 Dec 2025filed 2 Dec 2025INMB INmune Biooption or derivative · BiotechnologySEC FORM 4 Code A—150,000 at $0.00filing
18 Nov 2025filed 18 Nov 2025INMB INmune Biooption or derivative · BiotechnologySEC FORM 4 Code D—108,000filing
18 Nov 2025filed 18 Nov 2025INMB INmune Biooption or derivative · BiotechnologySEC FORM 4 Code A—108,000filing
18 Nov 2025filed 18 Nov 2025INMB INmune Biooption or derivative · BiotechnologySEC FORM 4 Code D—108,000filing
18 Nov 2025filed 18 Nov 2025INMB INmune Biooption or derivative · BiotechnologySEC FORM 4 Code A—108,000filing
18 Nov 2025filed 18 Nov 2025INMB INmune Biooption or derivative · BiotechnologySEC FORM 4 Code D—15,975filing
18 Nov 2025filed 18 Nov 2025INMB INmune Biooption or derivative · BiotechnologySEC FORM 4 Code A—15,975filing
18 Nov 2025filed 18 Nov 2025INMB INmune Biooption or derivative · BiotechnologySEC FORM 4 Code D—19,025filing
18 Nov 2025filed 18 Nov 2025INMB INmune Biooption or derivative · BiotechnologySEC FORM 4 Code A—19,025filing
18 Nov 2025filed 18 Nov 2025INMB INmune Biooption or derivative · BiotechnologySEC FORM 4 Code D—35,000filing
18 Nov 2025filed 18 Nov 2025INMB INmune Biooption or derivative · BiotechnologySEC FORM 4 Code A—35,000filing
18 Nov 2025filed 18 Nov 2025INMB INmune Biooption or derivative · BiotechnologySEC FORM 4 Code D—35,000filing
18 Nov 2025filed 18 Nov 2025INMB INmune Biooption or derivative · BiotechnologySEC FORM 4 Code A—35,000filing
18 Nov 2025filed 18 Nov 2025INMB INmune Biooption or derivative · BiotechnologySEC FORM 4 Code D—32,500filing
18 Nov 2025filed 18 Nov 2025INMB INmune Biooption or derivative · BiotechnologySEC FORM 4 Code A—32,500filing
18 Nov 2025filed 18 Nov 2025INMB INmune Biooption or derivative · BiotechnologySEC FORM 4 Code D—12,500filing

Sectors

Health Care7

Buys in green, sells in red, by the company’s sector.

Related people

Ronnie Duane ClarkDirector · Director at Inmune Bio, filing Form 4 there in the last year
James SapirsteinDirector · Director at Inmune Bio, filing Form 4 there in the last year
David J. MossChief Executive Officer · Chief Executive Officer at Inmune Bio, filing Form 4 there in the last year
Mark William LowdellChief Scientific Officer · Chief Scientific Officer at Inmune Bio, filing Form 4 there in the last year